来自官方财务报表的收入、利润与现金流历史。
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $714M | $502M | $222M | $9M | $78M | $70M | $8M | $41M | $0M | $0M |
| 毛利 | $666M | $474M | $218M | $7M | $74M | $67M | $8M | $38M | — | $0M |
| 毛利率% | 93.3% | 94.4% | 98.2% | 73.7% | 95.6% | 95.5% | 100.0% | 93.8% | — | — |
| 营业利润（EBIT） | ($543M) | ($569M) | ($593M) | ($607M) | ($512M) | ($577M) | ($474M) | ($266M) | ($184M) | ($44M) |
| 营业利润率% | -76.0% | -113.3% | -267.2% | -6528.7% | -659.6% | -827.1% | -5752.0% | -656.4% | — | — |
| 净利 | ($696M) | ($729M) | ($536M) | ($643M) | ($481M) | ($563M) | ($449M) | ($260M) | ($131M) | ($31M) |
| 净利润率 % | -97.5% | -145.3% | -241.4% | -6913.9% | -619.7% | -806.9% | -5439.7% | -642.1% | — | — |
| EBITDA | — | ($673M) | ($437M) | ($565M) | ($397M) | ($534M) | ($467M) | ($279M) | ($183M) | ($44M) |
| 每股收益（EPS） | $-3.58 | $-3.70 | $-2.88 | $-3.95 | $-3.26 | $-3.90 | $-3.80 | $-2.48 | $-1.42 | $-0.33 |
| 已发行股数 (M) | — | 197M | 186M | 163M | 147M | 144M | 118M | 105M | 92M | 92M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 BBIO 交互式查看器。 /companies/us/BBIO
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms